H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Verve Therapeutics (VERV) to $15 from $14 and keeps a Buy rating on the shares. The firm says the Q2 VERVE-101 data readout “should constitute a major inflection point” for the shares. It expects the data to be positive.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress
- Verve Therapeutics reports Q4 EPS (58c), consensus (67c)
- Is VERV a Buy, Before Earnings?
- Promising Outlook for Verve Therapeutics: Buy Rating Backed by Innovative Treatments and Strategic Partnerships
- Optimistic Outlook for Verve Therapeutics Amid Promising Developments and Strategic Partnerships